Our Take
A 10-point disease-free survival gap at three years is solid clinical evidence, but the real question is whether dMMR/MSI-H patients actually get tested and stratified before treatment starts.
Why it matters
Colon cancer remains the second leading cause of cancer death in the US, and identifying the dMMR subgroup unlocks immunotherapy benefit. FDA priority review means decision by October 2026, potentially expanding treatment options for a specific, biomarker-defined population.
Do this week
Oncologists and pathology leads: audit your stage III colon cancer testing protocols now to ensure dMMR/MSI-H status is captured prospectively, so you can enroll eligible patients immediately if approval lands.
Roche clears FDA priority-review threshold for Tecentriq combo
Roche has won FDA priority review for a supplemental biologics license application (sBLA) covering Tecentriq (atezolizumab) plus chemotherapy for stage III colon cancer patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) status. The agency is expected to make a decision by 9 October 2026.
The submission rests on Phase III data from the ATOMIC trial, published in The New England Journal of Medicine. The randomized, open-label, multicenter study enrolled 712 patients and compared Tecentriq combined with standard FOLFOX6 chemotherapy (folinic acid, fluorouracil, oxaliplatin) against chemotherapy alone in the adjuvant setting (post-surgical treatment).
Primary results showed a 50% reduction in recurrence or death risk with the combination (per company-reported data). At 36 months, disease-free survival was 86% in the Tecentriq plus chemotherapy arm versus 76% with chemotherapy only. The safety profile aligned with historical Tecentriq trials. Roche is also pursuing European Medicines Agency approval and other regulatory pathways to widen access.
Biomarker-driven precision matters more than the drug itself
The clinical win is genuine: a 10-point absolute disease-free survival advantage over three years is meaningful in adjuvant oncology, where the bar for approval is typically high and baseline outcomes are already strong. The real clinical value, however, lies in the dMMR/MSI-H stratification.
Patients with dMMR or MSI-H tumors have a specific immune profile that responds to PD-L1 blockade. This subset represents roughly 15% of stage III colon cancers, making this a precision play, not a population-wide shift. The trial design acknowledged this by enrolling only dMMR/MSI-H patients.
The bottleneck is implementation. Most U.S. pathology labs now perform MSI or dMMR testing as standard of care, but inconsistency remains. If treatment centers don't systematically identify and enroll these patients into adjuvant protocols post-approval, the survival benefit stays theoretical. The drug approval is the easier part; clinical adoption depends on testing discipline upstream.
Prepare testing and enrollment infrastructure now
If Tecentriq combo gains approval in 2026, the competitive and clinical advantage will accrue to centers that already have dMMR/MSI-H screening embedded in their stage III colon cancer diagnostic workflow. That means pathology, surgery, and medical oncology must align on which patients get tested, when, and how results are communicated to the treatment team.
Organizations without robust biomarker testing in place will face delays in patient identification and enrollment. Those with established testing pipelines and pathology-oncology communication protocols will move to treatment faster and capture the real-world benefit that the ATOMIC trial demonstrated.